Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Carcinoma
- Lung Neoplasms
- Non -Small Cell Lung Cancer
- Design
- Observational Model: Case-OnlyTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
Studies have shown the feasibility of detecting mutation status by blood and urine circulating tumor DNA (ctDNA)in non-small cell lung cancer (NSCLC) patients. However, no prospective has been conducted for usage of ctDNA in postoperative surveillance of NSCLC patients. We plan to compare tumor make...
Studies have shown the feasibility of detecting mutation status by blood and urine circulating tumor DNA (ctDNA)in non-small cell lung cancer (NSCLC) patients. However, no prospective has been conducted for usage of ctDNA in postoperative surveillance of NSCLC patients. We plan to compare tumor makers and radiographic approaches with blood and urine ctDNA in surveillance to assess the lead time of postoperative tumor relapse in stage ?A NSCLC patients. And evaluate the correlation between ctDNA level with tumor relapse or metastasis.
Tracking Information
- NCT #
- NCT02696525
- Collaborators
- San Valley Biotechnology Incorporated
- Investigators
- Principal Investigator: Jun Wang, M.D. Peking University People's Hospital Study Chair: Yilong Wu, M.D. Guang Dong General Hospital Study Director: Lin Xu, M.D. Jiang Su Cancer Hospital
Get Well Soon